[e-farmacos] WHO Pharmaceuticals Newsletter No. 5, 2005

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados,

Esta disponible el  WHO Pharmaceuticals Newsletter No. 5, 2005 con el siguiente indice:

Regulatory Matters
Ibritumomab - Skin reactions warning added to labels
Morphine sulfate extended release capsules -- Alcohol promotes rapid release
Pemoline -- Withdrawn due to liver toxicity risk
Tamsulosin hydrochloride -- Risk of Intraoperative Floppy Iris Syndrome (IFIS)

Safety of Medicines
Estrogen / progestin weekly patch -- Higher levels of estrogen than birth-control pills
Factor VIII (FVIII) recombinant products -- Risk of inhibitor development in
previously treated patients

Liqiang 4 dietary supplement -- Presence of glyburide
Meningococcal vaccine -- Reports of Guillain-Barré Syndrome
Menze Qianweishu slimming herbs capsule -- Found to contain sibutramine
Methadone -- Cardiac vigilance recommended
Nimodipine -- Serious events due to IV use of oral formulations
Oseltamivir -- Safety update

Problems of Current Interest
Nevirapine and serious liver adverse reactions: implications for fixed dose
combinations

Feature
Twenty-eighth Annual Meeting of Representatives of the National Centres
participating in the WHO Programme for International Drug Monitoring

se puede obtener en la siguiente direccion:
http://www.who.int/entity/medicines/publications/pn2005_5.pdf

Saludos,

Martin

Martin Canas
GAPURMED
La Plata
(Argentina)
macanas@netverk.com.ar